Rubio-Luengo M A, Maldonado-Martín A, Gil-Extremera B, González-Gómez L, Luna del Castillo J D
Hypertension Unit, University of Granada Hospital, Spain.
Am J Hypertens. 1995 Jul;8(7):689-95. doi: 10.1016/0895-7061(95)00079-5.
We studied the influence of captopril, atenolol, and verapamil on serum and intraerythrocyte concentrations of magnesium and zinc in 30 normotensive control subjects (12 men and 18 women, aged 30 to 65 years, mean +/- SD 45.76 +/- 12.15 years) and 30 patients with untreated mild or moderate essential hypertension (14 men and 16 women, aged 30 to 65 years, mean +/- SD 49.50 +/- 13.58 years). Ten each of the hypertensive patients were treated with captopril, atenolol, or verapamil. Physical examination and biochemical analyses (serum Mg and Zn) were done in all participants at baseline, and in patients after 3 and 6 months of treatment. The results were compared according to a nested design with Neumann-Keuls test. We found no significant differences between controls and patients in serum and intraerythrocyte concentrations of Zn at the start of the study, although there was a significant decrease in serum Zn in patients after 3 (P < .01) and 6 months (P < .001) of treatment, regardless of the drug used. This decrease was thought to be attributable to the zincuric effect of captopril or to dietary measures, or both. Intraerythrocyte Zn was not significantly affected by antihypertensive treatment. Serum and intraerythrocyte concentrations of Mg were significantly lower (P < .001) in hypertensive than in normotensive subjects, and serum Mg in patients treated with verapamil was significantly lower (P < .05) than after treatment with captopril or atenolol. Serum Mg concentration was related directly with serum concentrations of high density lipoprotein cholesterol (r = 0.4043, P < .05). We conclude that supplementation with Mg may benefit patients with hypertension.
我们研究了卡托普利、阿替洛尔和维拉帕米对30名血压正常的对照者（12名男性和18名女性，年龄30至65岁，平均±标准差45.76±12.15岁）以及30名未经治疗的轻度或中度原发性高血压患者（14名男性和16名女性，年龄30至65岁，平均±标准差49.50±13.58岁）血清及红细胞内镁和锌浓度的影响。每组10名高血压患者分别接受卡托普利、阿替洛尔或维拉帕米治疗。所有参与者在基线时以及患者治疗3个月和6个月后进行了体格检查和生化分析（血清镁和锌）。根据嵌套设计采用纽曼-凯尔斯检验对结果进行比较。我们发现，在研究开始时，对照组和患者的血清及红细胞内锌浓度无显著差异，不过无论使用何种药物，患者在治疗3个月（P<0.01）和6个月（P<0.001）后血清锌均显著降低。这种降低被认为归因于卡托普利的排锌作用或饮食措施，或两者皆有。降压治疗对红细胞内锌无显著影响。高血压患者的血清及红细胞内镁浓度显著低于血压正常者（P<0.001），且接受维拉帕米治疗的患者血清镁显著低于接受卡托普利或阿替洛尔治疗后（P<0.05）。血清镁浓度与高密度脂蛋白胆固醇的血清浓度直接相关（r=0.4043，P<0.05）。我们得出结论，补充镁可能对高血压患者有益。
